Caristo Diagnostics
PrivateLast Round
Series A
Apr 17, 2023
Total Funding Raised
$21.38M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Caristo Diagnostics operates in Healthcare & Life Sciences and is based in Oxford. Its latest recorded funding round was a Series A round in April 2023.
Caristo Diagnostics is a healthtech company that develops AI-powered diagnostic and risk prediction tools for cardiovascular and vascular diseases.
Sector
Healthcare & Life Sciences
Verticals
Medical Imaging, Medical AI, Medical Devices, Healthcare Analytics
Business Model
B2B
Customer Profile
Subscription SaaS, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Caristo Diagnostics Comparables
Compare Caristo Diagnostics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Artrya Ltd | 87% | |
| Spimed-AI | 84% | |
| Ultromics | 84% |
For institutional investors. Book with your work email.
Caristo Diagnostics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Apr 17, 2023 | ||||
| Grant | Oct 20, 2018 | ||||
| Seed | Oct 20, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Caristo Diagnostics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| BGF | Series A |
| Oxford Science Enterprises | Seed, Series A |
| University of Oxford | Series A |
| Oxford Technology Investment Fund | Seed |
| OTIF Ventures | Series A |
| Innovate UK | Grant |
| Longwall Venture Partners | Seed, Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 30% MoM, reaching 6.3K.
- Apr 14, 2026
Stephen M. Deitsch appointed as new Chief Executive Officer.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- attends_eventAug 24, 2026
Caristo's technology is featured in research presentations on non-contrast cardiac CT, stroke prediction, and virtual biopsy of arterial inflammation at ESC Congress in Germany from Aug 28th–31st '26.
For institutional investors. Book with your work email.
Caristo Diagnostics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Caristo Diagnostics's valuation, stock price, and market status.
Is Caristo Diagnostics a public or private company?
Caristo Diagnostics is a private company.
What is the current stock price of Caristo Diagnostics?
Caristo Diagnostics is a private company, so its shares have no public market price. Caplight tracks Caristo Diagnostics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Caristo Diagnostics worth (valuation)?
Valuation information for Caristo Diagnostics is not publicly available.
Can I buy Caristo Diagnostics stock?
Caristo Diagnostics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Caristo Diagnostics's last funding round?
Caristo Diagnostics's most recent funding round was Series A on April 17, 2023.
Who are the main investors in Caristo Diagnostics?
Key investors in Caristo Diagnostics include BGF, Oxford Science Enterprises.
Will Caristo Diagnostics IPO soon?
No public IPO plans have been announced for Caristo Diagnostics.
How can I track Caristo Diagnostics secondary market activity?
Caplight tracks bids, offers, and trades in Caristo Diagnostics's shares on secondary markets.